Henry J. Fuchs
2017
In 2017, Henry J. Fuchs earned a total compensation of $7M as President, Worldwide R&D at BioMarin Pharmaceutical, a 22% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $590,720 |
|---|---|
| Option Awards | $2,335,264 |
| Salary | $637,231 |
| Stock Awards | $3,460,084 |
| Other | $22,125 |
| Total | $7,045,424 |
Fuchs received $3.5M in stock awards, accounting for 49% of the total pay in 2017.
Fuchs also received $590.7K in non-equity incentive plan, $2.3M in option awards, $637.2K in salary and $22.1K in other compensation.
Rankings
In 2017, Henry J. Fuchs' compensation ranked 1,153rd out of 14,666 executives tracked by ExecPay. In other words, Fuchs earned more than 92.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,153 out of 14,666 | 92nd |
Division Manufacturing | 389 out of 5,772 | 93rd |
Major group Chemicals And Allied Products | 103 out of 2,075 | 95th |
Industry group Drugs | 70 out of 1,731 | 96th |
Industry Pharmaceutical Preparations | 57 out of 1,333 | 96th |
Source: SEC filing on April 23, 2019.
Fuchs' colleagues
We found four more compensation records of executives who worked with Henry J. Fuchs at BioMarin Pharmaceutical in 2017.
2017
Jean-Jacques Bienaim
BioMarin Pharmaceutical
Chief Executive Officer
2017
Daniel Spiegelman
BioMarin Pharmaceutical
Chief Financial Officer
2017
Jeff Ajer
BioMarin Pharmaceutical
Executive Vice President, Chief Commercial Officer
2017
Robert Baffi
BioMarin Pharmaceutical
Executive Vice President, Technical Operations
News
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2021 pay rises 1% to $18M
April 12, 2022
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2020 pay slips 2% to $18M
April 13, 2021
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2019 pay rises 18% to $18M
April 14, 2020
BioMarin Pharmaceutical CEO Jean-Jacques Bienaim's 2018 pay slips 2% to $16M
April 23, 2019